OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$8.20
-0.34 (-3.98%)
▼
5d:
-9.89%
30d:
+14.37%
90d:
+24.81%
HOLD
LOW Confidence
Last Updated: February 2, 2026
Earnings: Feb 12, 2026
8d
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.87
Based on 2.9% avg growth
INTRINSIC VALUE TODAY
$5.51
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $8.20, which is considered fair relative to its 30-day fair value range of $7.55 to $9.18. The stock's valuation (Forward PE: 2.1) is in line with its historical norms (2.0). At these levels, the market is pricing in 2.1% annual earnings growth.
Technical Outlook: Technically, OGN is in a downtrend. The price is currently testing key support at $8.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.36 (+14.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGN is in a downtrend. The price is currently testing key support at $8.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.36 (+14.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$7.55 -
$9.18
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading below Wall St target ($9.36)
- BULLISH: Expecting earnings turnaround to 2.1% growth with 1.3% revenue growth
- CAUTION: Recommendation downgraded due to -9.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$7.55 -
$9.18
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$8.08
Resistance Level
$9.94
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
2.14
Wall Street Target
$9.36
(+14.1%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
-55.8%
Profit Margin
8.0%
Valuation Premium vs History
+2.1% premium
PE vs Historical
2.1 vs 2.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.1%
(market-implied from PE analysis)
1-Year Target
$8.37
(+2%)
2-Year Target
$8.55
(+4%)
3-Year Target
$8.73
(+6%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$8.17
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 1.9%)
$90.59
(+1005%)
Base:
(SPY PE: 2.1, Growth: 1.9%)
$8.68
(+6%)
Bear:
(PE: 1.8, Growth: 1.9%)
$7.38
(-10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 4.49 | Current EPS (TTM): $1.90
Bull Case
$18.79
(+129%)
Analyst growth 100.0%, PE expands to 4.9
Base Case
$17.08
(+108%)
Market implied 100.0%, PE stable at 4.5
Bear Case
$5.81
(-29%)
Severe decline -20.0%, PE contracts to 3.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 03, 2026 1:25 AM ET
Data refreshes hourly during market hours. Next update: 2:25 AM
Data refreshes hourly during market hours. Next update: 2:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1146 | 55 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$139 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$333 | 69 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$193 | 57 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
